New Zealand markets closed

GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)

NSE - NSE Real-time price. Currency in INR
Add to watchlist
2,619.30+25.00 (+0.96%)
At close: 03:30PM IST
Currency in INR

Valuation measures4

Market cap (intra-day) 445.64B
Enterprise value 428.64B
Trailing P/E 83.87
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)13.40
Price/book (mrq)28.82
Enterprise value/revenue 12.94
Enterprise value/EBITDA 53.18

Trading information

Stock price history

Beta (5Y monthly) 0.22
52-week change 387.91%
S&P500 52-week change 323.49%
52-week high 32,650.00
52-week low 31,361.85
50-day moving average 32,074.36
200-day moving average 31,875.42

Share statistics

Avg vol (3-month) 3184.76k
Avg vol (10-day) 3319.68k
Shares outstanding 5169.41M
Implied shares outstanding 6170.14M
Float 841.37M
% held by insiders 175.58%
% held by institutions 19.45%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 432
Forward annual dividend yield 41.22%
Trailing annual dividend rate 332.00
Trailing annual dividend yield 31.23%
5-year average dividend yield 41.73
Payout ratio 4102.47%
Dividend date 3N/A
Ex-dividend date 431 May 2024
Last split factor 22:1
Last split date 311 Sept 2018

Financial highlights

Fiscal year

Fiscal year ends 31 Mar 2024
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 17.08%
Operating margin (ttm)25.72%

Management effectiveness

Return on assets (ttm)15.24%
Return on equity (ttm)33.53%

Income statement

Revenue (ttm)34.54B
Revenue per share (ttm)203.90
Quarterly revenue growth (yoy)18.10%
Gross profit (ttm)N/A
EBITDA 9.09B
Net income avi to common (ttm)5.9B
Diluted EPS (ttm)31.17
Quarterly earnings growth (yoy)45.80%

Balance sheet

Total cash (mrq)18.76B
Total cash per share (mrq)110.76
Total debt (mrq)186.7M
Total debt/equity (mrq)1.05%
Current ratio (mrq)1.84
Book value per share (mrq)104.93

Cash flow statement

Operating cash flow (ttm)5.82B
Levered free cash flow (ttm)6.78B